117 related articles for article (PubMed ID: 24741710)
1. Axes of differentiation in breast cancer: untangling stemness, lineage identity, and the epithelial to mesenchymal transition.
Granit RZ; Slyper M; Ben-Porath I
Wiley Interdiscip Rev Syst Biol Med; 2014; 6(1):93-106. PubMed ID: 24741710
[TBL] [Abstract][Full Text] [Related]
2. Evolving views of breast cancer stem cells and their differentiation States.
Condiotti R; Guo W; Ben-Porath I
Crit Rev Oncog; 2014; 19(5):337-48. PubMed ID: 25404149
[TBL] [Abstract][Full Text] [Related]
3. Stemness of the hybrid Epithelial/Mesenchymal State in Breast Cancer and Its Association with Poor Survival.
Grosse-Wilde A; Fouquier d'Hérouël A; McIntosh E; Ertaylan G; Skupin A; Kuestner RE; del Sol A; Walters KA; Huang S
PLoS One; 2015; 10(5):e0126522. PubMed ID: 26020648
[TBL] [Abstract][Full Text] [Related]
4. SLUG: Critical regulator of epithelial cell identity in breast development and cancer.
Phillips S; Kuperwasser C
Cell Adh Migr; 2014; 8(6):578-87. PubMed ID: 25482617
[TBL] [Abstract][Full Text] [Related]
5. OVOL2 links stemness and metastasis via fine-tuning epithelial-mesenchymal transition in nasopharyngeal carcinoma.
Qi XK; Han HQ; Zhang HJ; Xu M; Li L; Chen L; Xiang T; Feng QS; Kang T; Qian CN; Cai MY; Tao Q; Zeng YX; Feng L
Theranostics; 2018; 8(8):2202-2216. PubMed ID: 29721073
[No Abstract] [Full Text] [Related]
6. PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
Karicheva O; Rodriguez-Vargas JM; Wadier N; Martin-Hernandez K; Vauchelles R; Magroun N; Tissier A; Schreiber V; Dantzer F
Oncotarget; 2016 Sep; 7(39):64109-64123. PubMed ID: 27579892
[TBL] [Abstract][Full Text] [Related]
7. Introduction of SV40ER and hTERT into mammospheres generates breast cancer cells with stem cell properties.
Paranjape AN; Mandal T; Mukherjee G; Kumar MV; Sengupta K; Rangarajan A
Oncogene; 2012 Apr; 31(15):1896-909. PubMed ID: 21874052
[TBL] [Abstract][Full Text] [Related]
8. EZH2 promotes a bi-lineage identity in basal-like breast cancer cells.
Granit RZ; Gabai Y; Hadar T; Karamansha Y; Liberman L; Waldhorn I; Gat-Viks I; Regev A; Maly B; Darash-Yahana M; Peretz T; Ben-Porath I
Oncogene; 2013 Aug; 32(33):3886-95. PubMed ID: 22986524
[TBL] [Abstract][Full Text] [Related]
9. HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR.
Ingthorsson S; Andersen K; Hilmarsdottir B; Maelandsmo GM; Magnusson MK; Gudjonsson T
Oncogene; 2016 Aug; 35(32):4244-55. PubMed ID: 26686087
[TBL] [Abstract][Full Text] [Related]
10. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
[TBL] [Abstract][Full Text] [Related]
11. HOXA5 determines cell fate transition and impedes tumor initiation and progression in breast cancer through regulation of E-cadherin and CD24.
Teo WW; Merino VF; Cho S; Korangath P; Liang X; Wu RC; Neumann NM; Ewald AJ; Sukumar S
Oncogene; 2016 Oct; 35(42):5539-5551. PubMed ID: 27157614
[TBL] [Abstract][Full Text] [Related]
12. A role for partial epithelial-to-mesenchymal transition in enabling stemness in homeostasis and cancer.
Verstappe J; Berx G
Semin Cancer Biol; 2023 May; 90():15-28. PubMed ID: 36773819
[TBL] [Abstract][Full Text] [Related]
13. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.
Palafox M; Ferrer I; Pellegrini P; Vila S; Hernandez-Ortega S; Urruticoechea A; Climent F; Soler MT; Muñoz P; Viñals F; Tometsko M; Branstetter D; Dougall WC; González-Suárez E
Cancer Res; 2012 Jun; 72(11):2879-88. PubMed ID: 22496457
[TBL] [Abstract][Full Text] [Related]
14. Epithelial-Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance.
Gooding AJ; Schiemann WP
Mol Cancer Res; 2020 Sep; 18(9):1257-1270. PubMed ID: 32503922
[TBL] [Abstract][Full Text] [Related]
15. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
[TBL] [Abstract][Full Text] [Related]
16. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer.
West NR; Murray JI; Watson PH
Oncogene; 2014 Mar; 33(12):1485-94. PubMed ID: 23584474
[TBL] [Abstract][Full Text] [Related]
17. Plasticity between Epithelial and Mesenchymal States Unlinks EMT from Metastasis-Enhancing Stem Cell Capacity.
Beerling E; Seinstra D; de Wit E; Kester L; van der Velden D; Maynard C; Schäfer R; van Diest P; Voest E; van Oudenaarden A; Vrisekoop N; van Rheenen J
Cell Rep; 2016 Mar; 14(10):2281-8. PubMed ID: 26947068
[TBL] [Abstract][Full Text] [Related]
18. Revisiting epithelial-mesenchymal transition in cancer metastasis: the connection between epithelial plasticity and stemness.
Liao TT; Yang MH
Mol Oncol; 2017 Jul; 11(7):792-804. PubMed ID: 28649800
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity and Plasticity of Breast Cancer Stem Cells.
Sousa B; Ribeiro AS; Paredes J
Adv Exp Med Biol; 2019; 1139():83-103. PubMed ID: 31134496
[TBL] [Abstract][Full Text] [Related]
20. Reprogramming during epithelial to mesenchymal transition under the control of TGFβ.
Tan EJ; Olsson AK; Moustakas A
Cell Adh Migr; 2015; 9(3):233-46. PubMed ID: 25482613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
